Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The German National Strategy for Gene- and Cell-Based Therapies: Generating Impact by Employing a Novel Multi-Stakeholder Approach.

Human gene therapy·2026
Same author

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026
Same author

Capsid-engineered AAV vector overcomes a key intracellular barrier and efficiently transduces spiral ganglion neurons in adult mice.

Molecular therapy. Advances·2026
Same author

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026
Same author

Therapeutic antibody delivery: vector tools to boost efficacy and affordability.

Frontiers in immunology·2026
Same author

Robust Functionality and Regulation of Selectively Expressed RNA as AAV Vectors and In Vitro Transcribed Molecules.

Pharmaceutics·2025

Related Experiment Video

Updated: Apr 5, 2026

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants
09:20

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants

Published on: October 18, 2022

5.5K

Engineering the AAV capsid to optimize vector-host-interactions.

Hildegard Büning1, Anke Huber2, Liang Zhang2

  • 1Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany; Center for Molecular Medicine (CMMC), University of Cologne, Cologne, Germany; German Center for Infection Research (DZIF), Partner Sites Bonn-Cologne and Hannover-Braunschweig, Germany; Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany.

Current Opinion in Pharmacology
|August 25, 2015
PubMed
Summary
This summary is machine-generated.

Next-generation adeno-associated viral (AAV) vectors overcome limitations of earlier gene therapy systems. Engineered AAV vectors offer improved cell targeting and reduced immune responses for enhanced gene therapy applications.

More Related Videos

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
09:21

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

38.2K
Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

9.0K

Related Experiment Videos

Last Updated: Apr 5, 2026

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants
09:20

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants

Published on: October 18, 2022

5.5K
Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
09:21

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

38.2K
Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

9.0K

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Gene Therapy

Background:

  • Adeno-associated viral (AAV) vectors are crucial for in vivo gene therapy, with natural isolates showing clinical benefits for monogenetic disorders.
  • Limitations include high vector doses, pre-existing neutralizing antibodies, lack of cell-type selectivity leading to off-target transduction, and poor transduction of key cell types like stem cells.

Purpose of the Study:

  • To develop next-generation AAV vectors with enhanced capabilities for gene therapy.
  • To overcome limitations of natural AAV vectors, including immunogenicity, tropism, and transduction efficiency.

Main Methods:

  • Rational design and directed evolution strategies were employed to optimize AAV-host interactions.
  • Engineering efforts focused on improving cell transduction efficiency and targeting specific cell types.

Main Results:

  • Next-generation AAV vectors exhibit increased transduction efficiency.
  • Vectors demonstrate targeted transduction of previously non-permissive cell types.
  • Engineered vectors show escape from antibody neutralization and off-target-free in vivo delivery.

Conclusions:

  • Advanced AAV vector engineering significantly enhances gene therapy efficacy and safety.
  • These improvements are expected to broaden AAV-based applications in gene therapy and regenerative medicine.